Cipla Share Price in Focus; InvaGen Reports Zero Observations After USFDA Inspection

Written by: Team Angel OneUpdated on: 26 Oct 2026, 10:46 pm IST

Cipla InvaGen facility in New York completed a routine USFDA inspection with zero Form 483 observations.

Cipla has shared an update on its US subsidiary, InvaGen Pharmaceuticals. The company’s facility in Hauppauge, New York, recently underwent a routine USFDA inspection.

As per the exchange filing, the inspection was from October 19 to 22, 2026, and it ended with zero Form 483 observations, according to Cipla’s exchange filing dated October 23, 2026.

Inspection Completed Without Observations

The inspection covered InvaGen’s facility on Long Island. The USFDA concluded its visit without issuing any Form 483 observations, as reported by the company.

Cipla disclosed the outcome in a filing to the stock exchanges. The update relates specifically to the InvaGen facility and the inspection conducted during those four days.

Also Check: Pharmaceuticals Stocks

About Cipla

Cipla is a pharmaceutical company with operations in India and international markets. InvaGen Pharmaceuticals Inc., the facility covered in this update, is a wholly owned subsidiary of Cipla.

As of October 23, 2026, at 11:13 AM, Cipla share price was trading at ₹1,320.90 per share, reflecting a 0.75% decline from the previous closing price.

Conclusion

The inspection ended without any Form 483 observations at InvaGen’s New York facility. Cipla’s filing provides the company’s official account of the inspection outcome.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.

Published on: Oct 23, 2026, 12:12 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More